PDF(Pubmed)
Abstract：
OBJECTIVE: This study evaluated the correlation between maternal hepcidin and other biomarkers of iron status, markers of inflammation, and maternal body weight during pregnancy, as well as neurodevelopment in the offspring.
METHODS: PubMed, Web of Science, Scopus, and Embase were searched from inception until March 2022.
METHODS: Studies conducted among pregnant women without apparent pregnancy complications were included. Eligible studies reported correlation coefficients between maternal hepcidin and any outcomes of maternal biomarkers of iron status or inflammatory load during pregnancy, prenatal maternal body weight, and offspring neurodevelopment. Studies without correlation data were eligible if they quantitatively reported volumes of both maternal hepcidin and any marker of iron status and/or inflammatory load during gestation.
METHODS: Pooled correlation coefficients between maternal hepcidin and outcomes of interest were calculated using the Fisher r-to-Z transformation. Both fixed-effects and DerSimonian and Laird random-effects models were used to calculate pooled correlation coefficient. When meta-analysis was not feasible, results were descriptively synthesized.
RESULTS: Forty-six studies with 6624 participants were eligible. Hepcidin was significantly correlated with hemoglobin in the third trimester (r=0.21; 95% confidence interval, 0.1-0.32); ferritin in the first (r=0.31; 95% confidence interval, 0.01-0.61) and third trimester (r=0.35; 95% confidence interval, 0.23-0.48); soluble transferrin receptor in the second trimester (r=-0.27; 95% confidence interval, -0.4 to -0.14); total iron-binding capacity in the second trimester (r=0.37; 95% confidence interval, 0.24-0.50); and serum iron in the third trimester (r=0.11; 95% confidence interval, 0.02-0.19). Hepcidin was significantly correlated with the inflammatory marker interleukin-6 in the third trimester (r=0.26; 95% confidence interval, 0.17-0.34) and C-reactive protein in the second (r=0.16; 95% confidence interval, 0.03-0.30) and third trimester (r=0.28; 95% confidence interval, 0.04-0.52). Four out of 5 studies reported weak-to-moderate positive correlation between hepcidin and body mass index. Hepcidin levels varied across body mass index categories. No single study reported the relationship between maternal hepcidin and neurodevelopment in offspring.
CONCLUSIONS: Hepcidin weakly to moderately correlates with biomarkers of iron and inflammation in pregnancy.
METHODS: PubMed, Web of Science, Scopus, and Embase were searched from inception until March 2022.
METHODS: Studies conducted among pregnant women without apparent pregnancy complications were included. Eligible studies reported correlation coefficients between maternal hepcidin and any outcomes of maternal biomarkers of iron status or inflammatory load during pregnancy, prenatal maternal body weight, and offspring neurodevelopment. Studies without correlation data were eligible if they quantitatively reported volumes of both maternal hepcidin and any marker of iron status and/or inflammatory load during gestation.
METHODS: Pooled correlation coefficients between maternal hepcidin and outcomes of interest were calculated using the Fisher r-to-Z transformation. Both fixed-effects and DerSimonian and Laird random-effects models were used to calculate pooled correlation coefficient. When meta-analysis was not feasible, results were descriptively synthesized.
RESULTS: Forty-six studies with 6624 participants were eligible. Hepcidin was significantly correlated with hemoglobin in the third trimester (r=0.21; 95% confidence interval, 0.1-0.32); ferritin in the first (r=0.31; 95% confidence interval, 0.01-0.61) and third trimester (r=0.35; 95% confidence interval, 0.23-0.48); soluble transferrin receptor in the second trimester (r=-0.27; 95% confidence interval, -0.4 to -0.14); total iron-binding capacity in the second trimester (r=0.37; 95% confidence interval, 0.24-0.50); and serum iron in the third trimester (r=0.11; 95% confidence interval, 0.02-0.19). Hepcidin was significantly correlated with the inflammatory marker interleukin-6 in the third trimester (r=0.26; 95% confidence interval, 0.17-0.34) and C-reactive protein in the second (r=0.16; 95% confidence interval, 0.03-0.30) and third trimester (r=0.28; 95% confidence interval, 0.04-0.52). Four out of 5 studies reported weak-to-moderate positive correlation between hepcidin and body mass index. Hepcidin levels varied across body mass index categories. No single study reported the relationship between maternal hepcidin and neurodevelopment in offspring.
CONCLUSIONS: Hepcidin weakly to moderately correlates with biomarkers of iron and inflammation in pregnancy.
摘要：
目的：本研究评估了母体铁调素与其他铁状态生物标志物之间的相关性，炎症的标志，和孕妇在怀孕期间的体重，以及后代的神经发育。
方法：PubMed，WebofScience,Scopus,和Embase从一开始一直搜索到2022年3月。
方法：纳入了在无明显妊娠并发症的孕妇中进行的研究。合格的研究报告了母体铁调素与妊娠期间铁状态或炎症负荷的母体生物标志物的任何结果之间的相关系数。产前产妇体重，和后代神经发育。如果没有相关性数据的研究定量报告了母体铁调素和妊娠期间铁状态和/或炎性负荷的任何标志物的体积，则它们是合格的。
方法：使用Fisherr-Z转换计算母体铁调素与目标结局之间的合并相关系数。固定效应以及DerSimonian和Laird随机效应模型均用于计算合并相关系数。当荟萃分析不可行时，结果进行描述性合成。
结果：符合资格的有6624名参与者的46项研究。铁调素与妊娠晚期血红蛋白显著相关(r=0.21;95%置信区间,0.1-0.32)；第一铁蛋白(r=0.31；95%置信区间，0.01-0.61)和孕晚期(r=0.35；95%置信区间，0.23-0.48）；妊娠中期的可溶性转铁蛋白受体（r=-0.27；95％置信区间，-0.4至-0.14）；妊娠中期的总铁结合能力（r=0.37；95％置信区间，0.24-0.50）；妊娠晚期的血清铁（r=0.11；95％置信区间，0.02-0.19）。铁调素与妊娠晚期炎症标志物白细胞介素-6显著相关(r=0.26;95%置信区间,0.17-0.34）和第二个C反应蛋白（r=0.16；95％置信区间，0.03-0.30)和孕晚期(r=0.28；95%置信区间，0.04-0.52）。5项研究中有4项报道了铁调素与体重指数之间的弱至中度正相关。铁调素水平因体重指数类别而异。没有一项研究报道母体铁调素与后代神经发育之间的关系。
结论：铁调素与妊娠中铁和炎症的生物标志物弱相关。
方法：PubMed，WebofScience,Scopus,和Embase从一开始一直搜索到2022年3月。
方法：纳入了在无明显妊娠并发症的孕妇中进行的研究。合格的研究报告了母体铁调素与妊娠期间铁状态或炎症负荷的母体生物标志物的任何结果之间的相关系数。产前产妇体重，和后代神经发育。如果没有相关性数据的研究定量报告了母体铁调素和妊娠期间铁状态和/或炎性负荷的任何标志物的体积，则它们是合格的。
方法：使用Fisherr-Z转换计算母体铁调素与目标结局之间的合并相关系数。固定效应以及DerSimonian和Laird随机效应模型均用于计算合并相关系数。当荟萃分析不可行时，结果进行描述性合成。
结果：符合资格的有6624名参与者的46项研究。铁调素与妊娠晚期血红蛋白显著相关(r=0.21;95%置信区间,0.1-0.32)；第一铁蛋白(r=0.31；95%置信区间，0.01-0.61)和孕晚期(r=0.35；95%置信区间，0.23-0.48）；妊娠中期的可溶性转铁蛋白受体（r=-0.27；95％置信区间，-0.4至-0.14）；妊娠中期的总铁结合能力（r=0.37；95％置信区间，0.24-0.50）；妊娠晚期的血清铁（r=0.11；95％置信区间，0.02-0.19）。铁调素与妊娠晚期炎症标志物白细胞介素-6显著相关(r=0.26;95%置信区间,0.17-0.34）和第二个C反应蛋白（r=0.16；95％置信区间，0.03-0.30)和孕晚期(r=0.28；95%置信区间，0.04-0.52）。5项研究中有4项报道了铁调素与体重指数之间的弱至中度正相关。铁调素水平因体重指数类别而异。没有一项研究报道母体铁调素与后代神经发育之间的关系。
结论：铁调素与妊娠中铁和炎症的生物标志物弱相关。
